{"id":59709,"date":"2026-03-17T13:23:53","date_gmt":"2026-03-17T05:23:53","guid":{"rendered":"https:\/\/flcube.com\/?p=59709"},"modified":"2026-03-17T13:23:53","modified_gmt":"2026-03-17T05:23:53","slug":"beone-innovation-center-and-voyagers-capital-launch-fund-early-stage-drug-investment-vehicle-targets-guangzhou-biotech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59709","title":{"rendered":"BeOne Innovation Center and Voyagers Capital Launch Fund \u2013 Early-Stage Drug Investment Vehicle Targets Guangzhou Biotech"},"content":{"rendered":"\n

The BeOne Innovation Center (BIC)<\/strong> and Voyagers Capital<\/strong> jointly announced the establishment of the “BeOne Voyagers Innovation Fund”<\/strong> in Guangzhou<\/strong>, with first closing limited partners (LPs)<\/strong> including leading pharmaceutical companies<\/strong> previously backed by BIC: BoYa Bio, Sansure Biotech, Chemexpress, Saifu Laboratories, Lummy Pharmaceutical, and HitGen<\/strong>. The fund will focus on early-stage investments in innovative drugs<\/strong>, leveraging BIC’s incubation expertise<\/strong> and Voyagers Capital’s investment track record<\/strong> to accelerate scientific research commercialization<\/strong> through deep industrial resource networks<\/strong>.<\/p>\n\n\n\n

Fund Structure and Partnership<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Fund Name<\/strong><\/td>BeOne Voyagers Innovation Fund<\/td><\/tr>
General Partners<\/strong><\/td>BeOne Innovation Center (BIC) + Voyagers Capital<\/td><\/tr>
Location<\/strong><\/td>Guangzhou, China<\/td><\/tr>
LP Syndicate<\/strong><\/td>BoYa Bio, Sansure Biotech, Chemexpress, Saifu Laboratories, Lummy Pharmaceutical, HitGen<\/td><\/tr>
LP Profile<\/strong><\/td>Leading companies across pharmaceutical sub-sectors (prior BIC portfolio)<\/td><\/tr>
Investment Focus<\/strong><\/td>Early-stage innovative drugs<\/td><\/tr>
Strategic Value<\/strong><\/td>Industrial resource integration; research commercialization acceleration<\/td><\/tr>
Announcement Date<\/strong><\/td>13\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale and Ecosystem Play<\/h2>\n\n\n\n
Component<\/th>Strategic Contribution<\/th><\/tr><\/thead>
BIC Incubation Expertise<\/strong><\/td>Proven track record nurturing biotech startups; laboratory and infrastructure support<\/td><\/tr>
Voyagers Capital<\/strong><\/td>Investment acumen; portfolio management; exit execution<\/td><\/tr>
Corporate LP Network<\/strong><\/td>Strategic investors providing: \u2022 Market intelligence
\u2022 Commercial partnerships
\u2022 Manufacturing capabilities
\u2022 Distribution channels<\/td><\/tr>
Guangzhou Hub<\/strong><\/td>Access to Greater Bay Area biotech cluster; government policy support; talent pool<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

LP Portfolio and Synergies<\/h2>\n\n\n\n
LP Company<\/th>Sub-Sector<\/th>Strategic Value to Fund<\/th><\/tr><\/thead>
BoYa Bio<\/strong><\/td>[Biologics\/CDMO]<\/td>Manufacturing scale-up capabilities<\/td><\/tr>
Sansure Biotech<\/strong><\/td>[Diagnostics\/molecular]<\/td>Companion diagnostic development<\/td><\/tr>
Chemexpress<\/strong><\/td>[Chemical synthesis\/CRO]<\/td>Medicinal chemistry and API synthesis<\/td><\/tr>
Saifu Laboratories<\/strong><\/td>[Preclinical research]<\/td>DMPK and safety assessment<\/td><\/tr>
Lummy Pharmaceutical<\/strong><\/td>[Formulation development]<\/td>Drug delivery technologies<\/td><\/tr>
HitGen<\/strong><\/td>[DNA-encoded libraries]<\/td>Early-stage drug discovery platforms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Ecosystem Integration:<\/strong><\/p>\n\n\n\n